ISET® test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells - PRNewswire

-

PARIS, Oct. 28, 2020 /PRNewswire/ -- Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine's (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) positive Circulating Tumor Cells (CTC).

The peer-reviewed article published in the journal Frontiers in Oncology (article), shows that the prostate cancer test based on CTC harvested with the ISET® technology and identified by the Immuno-Cytochemistry (ICC) PSA marker has an estimated positive-predictive-value (PPV) of 99% and negative-predictive-value (NPV) of 97%, providing a more reliable screening test for prostate cancer than the standard PSA blood test (PPV = 25%; NPV = 15.5%).  

Prostate cancer is the second most common cancer and the fifth leading cause of cancer deaths in men worldwide. Due to the limited sensitivity and specificity of the standard PSA test, a relevant proportion, close to 75%, of unnecessary prostate biopsies are performed every year, generating avoidable costs and suffering.

"This new non-invasive test based on ISET® technology allows for early detection of prostate cancer more accurately than the standard PSA test. Improving the accuracy of tests for early cancer detection may reduce the burden of unnecessary biopsies," said NIIM Director of Research, and Chief Investigator Associate Professor Karin Ried.

Davide Brechot, Deputy Director and CTO at Rarecells commented: "NIIM's preliminary data obtained with the ISET® technology opens the way to a more reliable prostate cancer screening test driving earlier curative interventions while reducing unnecessary, painful and costly prostate biopsies. They add to the body of published evidence of ISET® technology's excellence in cancer diagnostics and management "

ISET® has been validated by more than 85 independent scientific publications on 3,400 cancer patients and more than 1,200 cancer-free individuals (see www.rarecells.com). It demonstrates unparalleled performance for the isolation and characterization of individual CTC and CTC clusters.

About RARECELLS (www.rarecells.com)

Rarecells develops high value, innovative diagnostic tests in the fields of liquid biopsy and early cancer diagnostics. The company is the exclusive licensee of the ISET® patent portfolios owned by University of Paris, INSERM and Assistance Publique-Hôpitaux de Paris (AP-HP).

Logo - https://ift.tt/2GD21kS

[email protected]

SOURCE Rarecells, Inc.

Related Links

https://ift.tt/3jLqemZ



Comments

Post a Comment

Popular posts from this blog

Q&A

-
Image
prostate calcification treatment :: Article Creator Treatment Options For Different Stages Of Prostate Cancer Have you or a loved one been diagnosed with prostate cancer? Understanding the various treatment options available for different stages of this disease can empower you to make informed decisions. Navigating the journey through prostate cancer treatment starts with gaining knowledge about how the disease is categorized and what treatments align with each stage. Whether dealing with an early diagnosis or tackling more advanced stages, a spectrum of approaches is designed to manage the disease effectively. This information provides clarity and hope, showcasing the advancements in medical science that are helping individuals lead healthier lives post-diagnosis. Patients and their families need to engage in open discussions with healthcare professionals to understand each treatment option's potential outcomes and side effects. With this...
Read more

Sentinel lymph node biopsy: What cancer patients should know

-
Image
cancer lump on neck :: Article Creator Doctor Watching TV Show Spotted Cancer On Show's Guest That She Didn't Know About Say what you will about social media and daytime TV, but sometimes, they can help work wonders. In fact, the power of Facebook and the popularity of HGTV's Beachfront Bargain Hunt played a big part in helping Nicole McGuiness get ahead of her serious cancer diagnosis - but it was an eagle-eyed doctor who really saved her bacon. The then-32-year-old appeared on the property series alongside her father while in search of a holiday home in North Carolina to celebrate her recent recovery from brain cancer in May 2018. She explained that she had set her sights on 'something near the water', specifically a beachfront property in Morehead City, to start afresh in this new phase of her life. Dr. Erich Voigt was one of the viewers who tuned into the Beachfront Bargain Hunt episode, which Nicole featured in, an...
Read more

I Wish I Didn't Need an Oncologist at All, But I'm Thankful for the One ...

-
Image
efudex side effects :: Article Creator Inmates Given Ivermectin In Jail Will Each Get $2,000 After Settlement Your browser is not supporteddetroitnews.Com detroitnews.Com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use. Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on detroitnews.Com Efudex Cream Efudex Cream Generic Name & Formulations General Description Fluorouracil 5%. Pharmacological Class Antimetabolite. How Supplied Soln (w. Drop dispenser)—10mL, 25mL; Crm—40g Efudex Cream Indications Indications Multiple actinic or solar keratoses. Superficial basal cell carcinoma when conventional therapy is impractical (5% only); see full labeling. Efudex Cream Dosage and Administration Adult Keratoses: Apply twice daily until eros...
Read more